- Home
- TNXP
as 11-21-2024 4:00pm EST
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | CHATHAM |
| Market Cap: | 19.5M | IPO Year: | N/A |
| Target Price: | $53.50 | AVG Volume (30 days): | 51.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.12 - $22.08 | Next Earning Date: | 11-12-2024 |
| Revenue: | $11,291,000 | Revenue Growth: | 183.05% |
| Revenue Growth (this year): | 62.53% | Revenue Growth (next year): | 26.17% |
Latest Tonix Pharmaceuticals Holding Corp. News
TNXP Breaking Stock News: Dive into TNXP Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Tonix Pharmaceuticals to Present at the Winter 2024 Investor Summit Virtual
GlobeNewswire
4 days ago
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting
ACCESSWIRE
8 days ago
Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments
GlobeNewswire
9 days ago
Tonix Pharmaceuticals Announces Poster Presentation at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting
GlobeNewswire
9 days ago
Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company’s Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals
TipRanks
17 days ago
Tonix Pharma Partners for Vaccine Clinical Trial
GlobeNewswire
18 days ago
Tonix Pharmaceuticals Announces Research Agreement with Kenya Medical Research Institute (KEMRI) to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya
GlobeNewswire
21 days ago
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024
Compare TNXP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TNXP Tonix Pharmaceuticals Holding Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.